Key result
In a retrospective analysis of 1,550 patients, CRT-D was associated with lower total mortality compared to CRT-P (HR 0.72), emphasizing the need for the upcoming randomized RESET-CRT trial.
Why the study?
Does CRT-D reduce total mortality compared to CRT-P in heart failure patients with reduced LVEF and a CRT indication?
Does CRT-D reduce total mortality compared to CRT-P in heart failure patients with reduced LVEF and a CRT indication?
Hazard Ratio: 0.72
No takes yet. Share an insight, caveat, or question.
There is a critical need for randomized controlled trials, such as the upcoming RESET-CRT, to determine whether the addition of a defibrillator to cardiac resynchronization therapy improves survival compared to pacing alone in heart failure patients.
Dagres et al. (2018) conducted an editorial in Heart failure (n=1,550). Cardiac resynchronization therapy with defibrillator (CRT-D) vs. Cardiac resynchronization therapy with pacemaker (CRT-P) was evaluated on Total mortality (HR 0.72). In a retrospective analysis of 1,550 patients, CRT-D was associated with lower total mortality compared to CRT-P (HR 0.72), emphasizing the need for the upcoming randomized RESET-CRT trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: